Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 241–250 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 241
- Medicine slug
- candesartan-cilexetil
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
15%
- Numeric value
- 15
- Unit
- %
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a59260-d2b6-464a-b5b9-bbc599e57e10 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d23fe59a-2ad6-4885-a0d8-2239048f05a3 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4621249c-1f44-4d95-8513-a1a2b1859e41 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f2b2fa3-249b-4756-a3f1-3223a004d9cb (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9afc130e-a784-49fe-9772-27c492724f08 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5b43fa0-6678-4219-99f1-10d273d49baf (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:904b357e-97bf-475e-90a5-f0449f2a428e (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15601654-76da-04cf-e063-6394a90a2cb5 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a515af5-bd53-43f1-b40a-aa0f332bc2ab (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.
Projected row 242
- Medicine slug
- candesartan-cilexetil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
9 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a59260-d2b6-464a-b5b9-bbc599e57e10 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d23fe59a-2ad6-4885-a0d8-2239048f05a3 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4621249c-1f44-4d95-8513-a1a2b1859e41 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f2b2fa3-249b-4756-a3f1-3223a004d9cb (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9afc130e-a784-49fe-9772-27c492724f08 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5b43fa0-6678-4219-99f1-10d273d49baf (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:904b357e-97bf-475e-90a5-f0449f2a428e (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15601654-76da-04cf-e063-6394a90a2cb5 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a515af5-bd53-43f1-b40a-aa0f332bc2ab (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
The elimination half-life of candesartan is approximately 9 hours.
Projected row 243
- Medicine slug
- candesartan-cilexetil
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a59260-d2b6-464a-b5b9-bbc599e57e10 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d23fe59a-2ad6-4885-a0d8-2239048f05a3 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4621249c-1f44-4d95-8513-a1a2b1859e41 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f2b2fa3-249b-4756-a3f1-3223a004d9cb (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9afc130e-a784-49fe-9772-27c492724f08 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5b43fa0-6678-4219-99f1-10d273d49baf (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:904b357e-97bf-475e-90a5-f0449f2a428e (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (> 99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15601654-76da-04cf-e063-6394a90a2cb5 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a515af5-bd53-43f1-b40a-aa0f332bc2ab (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
Projected row 244
- Medicine slug
- candesartan-cilexetil
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
0.13 L/kg
- Numeric value
- 0.13
- Unit
- L/kg
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a59260-d2b6-464a-b5b9-bbc599e57e10 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d23fe59a-2ad6-4885-a0d8-2239048f05a3 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4621249c-1f44-4d95-8513-a1a2b1859e41 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f2b2fa3-249b-4756-a3f1-3223a004d9cb (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9afc130e-a784-49fe-9772-27c492724f08 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5b43fa0-6678-4219-99f1-10d273d49baf (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:904b357e-97bf-475e-90a5-f0449f2a428e (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15601654-76da-04cf-e063-6394a90a2cb5 (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a515af5-bd53-43f1-b40a-aa0f332bc2ab (opens source in a new tab)
Candesartan Cilexetil label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg.
Projected row 245
- Medicine slug
- cangrelor
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
97 to 98%
- Numeric value
- 97
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c86264c2-ef49-4524-b6af-edb7a6279faa (opens source in a new tab)
Cangrelor label
Version not recorded · Effective date not recorded
Plasma protein binding of cangrelor is about 97 to 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b434fa-8891-4fd5-9d86-7ea64667c08f (opens source in a new tab)
Cangrelor label
Version not recorded · Effective date not recorded
Plasma protein binding of KENGREAL is about 97-98%.
Projected row 246
- Medicine slug
- cangrelor
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
3.9 L
- Numeric value
- 3.9
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c86264c2-ef49-4524-b6af-edb7a6279faa (opens source in a new tab)
Cangrelor label
Version not recorded · Effective date not recorded
Distribution In a study in healthy volunteers, cangrelor administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b434fa-8891-4fd5-9d86-7ea64667c08f (opens source in a new tab)
Cangrelor label
Version not recorded · Effective date not recorded
Distribution In a study in healthy volunteers, KENGREAL administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L.
Projected row 247
- Medicine slug
- capecitabine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
0.75 hour
- Numeric value
- 0.75
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f555b6b-60db-45e2-a61e-537e57f43fdc (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
The elimination half-life of both parent capecitabine and 5-FU was about 0.75 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2871c37d-5e55-437b-a434-fc86d845492a (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
The elimination half-life of both parent capecitabine and 5-FU was about 0.75 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f050d16c-ab76-489d-b92c-8c155b4e3f7c (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
The elimination half-life of both parent capecitabine and 5-FU was about 0.75 hour.
Projected row 248
- Medicine slug
- capecitabine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
60%
- Numeric value
- 60
- Unit
- %
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ec2cfc1-e8ca-4109-8b90-1aab07cbab21 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2777b481-7d7f-461a-b5e0-c09ce2990c34 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88c5af84-900a-4372-b056-bfea70c129cf (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c873e5b-51c2-4685-86c5-53f98563b093 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e28a5ef7-4731-f8ac-e053-2995a90a21bf (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06a88b03-6c06-4dae-b3bc-1e8dd81c9067 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56441153-a1e5-4fdc-96d6-f21baa6b5fbe (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f555b6b-60db-45e2-a61e-537e57f43fdc (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8345d55e-ad02-4726-a04b-1a46e3337a4b (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b59e98c-5b34-4b93-90f6-20526f4d4f88 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b1a2b5-f1ce-45ea-afd8-68aac53665fa (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e702d84d-7162-4751-bf37-d724cc7e45a5 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5753679a-506c-4ac4-b8b2-b27c664d1d40 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2871c37d-5e55-437b-a434-fc86d845492a (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f050d16c-ab76-489d-b92c-8c155b4e3f7c (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb12406-ce02-3f31-e053-2995a90a0b16 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e7d6317-1439-4976-ae00-6f62619ec3dd (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d23f023a-ea62-4ac0-f615-d5d26d59526d (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643a31d6-0e30-4602-a9b4-355fe944bfea (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.Capecitabine was primarily bound to human albumin (approximately 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29885ada-b743-419c-8f15-edd4247c76ca (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:007e3432-c8aa-2a76-52ba-c346924c08a7 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent.
Projected row 249
- Medicine slug
- capecitabine
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 0.857143
- Recorded readings
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 18
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 18 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ec2cfc1-e8ca-4109-8b90-1aab07cbab21 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine tablets 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2777b481-7d7f-461a-b5e0-c09ce2990c34 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88c5af84-900a-4372-b056-bfea70c129cf (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c873e5b-51c2-4685-86c5-53f98563b093 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of Capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e28a5ef7-4731-f8ac-e053-2995a90a21bf (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06a88b03-6c06-4dae-b3bc-1e8dd81c9067 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine tablets 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56441153-a1e5-4fdc-96d6-f21baa6b5fbe (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8345d55e-ad02-4726-a04b-1a46e3337a4b (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b59e98c-5b34-4b93-90f6-20526f4d4f88 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b1a2b5-f1ce-45ea-afd8-68aac53665fa (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e702d84d-7162-4751-bf37-d724cc7e45a5 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of XELODA 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5753679a-506c-4ac4-b8b2-b27c664d1d40 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb12406-ce02-3f31-e053-2995a90a0b16 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e7d6317-1439-4976-ae00-6f62619ec3dd (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d23f023a-ea62-4ac0-f615-d5d26d59526d (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine tablets 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median Tmax of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643a31d6-0e30-4602-a9b4-355fe944bfea (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the medianT max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29885ada-b743-419c-8f15-edd4247c76ca (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median T max of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:007e3432-c8aa-2a76-52ba-c346924c08a7 (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
Absorption Following oral administration of capecitabine tablets 1,255 mg/m 2 orally twice daily (the recommended dosage when used as single agent), the median Tmax of capecitabine and its metabolite fluorouracil was approximately 1.5 hours and 2 hours, respectively.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f555b6b-60db-45e2-a61e-537e57f43fdc (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration of 1255 mg/m 2 BID to cancer patients, capecitabine reached peak blood levels in about 1.5 hours (T max ) with peak 5-FU levels occurring slightly later, at 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2871c37d-5e55-437b-a434-fc86d845492a (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
This metabolic error can interfere with RNA processing and protein synthesis. 12.3 Pharmacokinetics Absorption Following oral administration of 1,255 mg/m 2 BID to cancer patients, capecitabine reached peak blood levels in about 1.5 hours (T max ) with peak 5-FU levels occurring slightly later, at 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f050d16c-ab76-489d-b92c-8c155b4e3f7c (opens source in a new tab)
Capecitabine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration of 1255 mg/m 2 BID to cancer patients, capecitabine reached peak blood levels in about 1.5 hours (T max ) with peak 5-FU levels occurring slightly later, at 2 hours.
Projected row 250
- Medicine slug
- captopril
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a43a5373-ded9-4912-8c98-edaec8352836 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1395ba5b-2fc9-41ff-9c43-e0740d781dee (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66604c8e-f6b6-4cf9-9561-f1cb4af0e0d6 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fbc9b28-ff10-4b17-a359-e12b4330747e (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b789f16-b291-4012-be39-af3beec3ff9a (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b54feb0-13cd-46a8-9924-f12880381196 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b44ab6e-6cd9-4e12-b9be-d2e4d954acb5 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a91ac7f-b75d-d111-e063-6394a90a2a93 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:563737c5-4d63-4957-8022-e3bc3112dfac (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65ed6e70-f1ee-437e-965c-d1b1fdadd832 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d117c8bd-50a8-7355-e053-2a95a90ac70f (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3362b7a8-026a-b277-e063-6394a90a9dc6 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d3779b0-83d9-4b6f-a043-f7768cd7fce6 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccbffd30-4b21-4522-bdb8-abba8d592017 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:607687f4-63cf-411c-a20b-21d238a6b7a7 (opens source in a new tab)
Captopril label
Version not recorded · Effective date not recorded
The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=240Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.